Becton, Dickinson and Company (NYSE:BDX) Announces Earnings Results, Beats Expectations By $0.09 EPS

Becton, Dickinson and Company (NYSE:BDX) posted its earnings results on Thursday. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09, FiscalAI reports. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the company posted $3.68 EPS. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company updated its FY 2026 guidance to 12.620-12.720 EPS.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• Third-quarter results exceeded expectations, with revenue of $5.0 billion up 4.4%, adjusted operating margin of 24.9%, and adjusted EPS of $3.23, up 4.9%.
• Growth was broad-based, with more than 90% of the portfolio delivering high-single-digit growth and double-digit expansion in biologic drug delivery, advanced patient monitoring, PureWick, advanced tissue regeneration, and pharmacy automation. BD also cited share gains and strong momentum from new product launches and targeted commercial investments.
• BD raised the midpoint of its fiscal 2026 adjusted EPS outlook to $12.62–$12.72 and expects revenue growth toward the high end of its low-double-digit FX-neutral range; currency is currently expected to provide an approximately 100-basis-point revenue tailwind.
• Management expects fiscal 2027 revenue growth to remain in the low-single-digit range, partly because the end of Alaris remediation creates an approximately 200-basis-point headwind. Tariffs reduced third-quarter margin by about 110 basis points, while oil, resin costs, and broader market conditions remain risks.
• Year-to-date free cash flow rose 45% to $1.7 billion, supporting $3.1 billion of shareholder returns, including approximately $2.3 billion in share repurchases and $0.9 billion in dividends.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded up $6.74 during mid-day trading on Thursday, reaching $177.40. 3,285,180 shares of the company were exchanged, compared to its average volume of 1,774,036. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $48.88 billion, a PE ratio of 44.91, a PEG ratio of 12.16 and a beta of 0.19. The company’s 50 day moving average price is $153.78 and its 200 day moving average price is $162.41.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported fiscal Q3 revenue of approximately $5.0 billion, up 5.4% year over year and ahead of the $4.89 billion consensus estimate. Broad growth across its Medical Essentials and Interventional segments helped offset weaker areas. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Adjusted diluted EPS was $3.23, beating analysts’ $3.14 estimate by $0.09. The company raised its fiscal 2026 adjusted EPS guidance to $12.62-$12.72, above the roughly $12.56 consensus, and expects revenue growth toward the high end of its previous range. Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
• Positive Sentiment: BD reported solid cash-flow improvement: year-to-date cash from continuing operations rose 33.3% to $2.1 billion, while free cash flow increased 44.6% to $1.7 billion. This supports balance-sheet flexibility and the company’s earnings-quality narrative. BD Reports Third Quarter Fiscal 2026 Financial Results

Analyst Upgrades and Downgrades

BDX has been the topic of several research analyst reports. Wells Fargo & Company upped their price target on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Jefferies Financial Group restated a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday. Piper Sandler decreased their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Finally, Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a report on Tuesday, April 14th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $183.53.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at $16,122,355.05. The trade was a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 5,189 shares of company stock worth $765,661. 0.40% of the stock is owned by insiders.

Institutional Trading of Becton, Dickinson and Company

A number of hedge funds have recently bought and sold shares of the company. Ausdal Financial Partners Inc. raised its position in shares of Becton, Dickinson and Company by 4.0% in the 4th quarter. Ausdal Financial Partners Inc. now owns 2,544 shares of the medical instruments supplier’s stock worth $494,000 after purchasing an additional 97 shares during the last quarter. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company in the 3rd quarter worth about $25,000. Bank of Jackson Hole Trust grew its position in Becton, Dickinson and Company by 28.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 649 shares of the medical instruments supplier’s stock valued at $126,000 after purchasing an additional 145 shares during the last quarter. Prosperity Bancshares Inc bought a new stake in Becton, Dickinson and Company during the 4th quarter valued at about $29,000. Finally, Zions Bancorporation National Association UT increased its stake in Becton, Dickinson and Company by 18.3% during the 4th quarter. Zions Bancorporation National Association UT now owns 962 shares of the medical instruments supplier’s stock valued at $187,000 after purchasing an additional 149 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.